Moreover, when TYRO3 was co-expressed with other TAM receptors, the effects of TYRO3 silencing were consistently more important than those of AXL or MERTK knockdown, highlighting the predominant role of TYRO3 in the modulation of bladder cancer cell viability and suggesting the potential for therapeutic targeting of TYRO3 (Fig. 2b). The gene discussed is MERTK; the disease is urinary bladder carcinoma.